Authors

  • Axmatova K.A., Azizova D.M.

Keywords:

PCSK9, multifokal ateroskleroz, eksperimental model, lipid almashinuvi, LDL-R, biomarker, yallig‘lanish, tomir patologiyasi

References

Д.М.Азизова, И.Р.Мавлянов, Р.А.Сабирова, М.У.Кулманова, А.Б.Солиев, Г.Ж.Жарылкасынова. Разработка новых подходов к коррекции гиперлипидемии с учётом изменения жирнокислотного состава сыворотки крови//Анализ риска здоровью. – 2020. - № 2. – С. 152-163. DOI: 10.21668/health.risk/2020.2.17

Stoekenbroek RM, et al. PCSK9: From basic science to clinical practice. Nature Reviews Cardiology. 2018;15(3):155–165.

Abifadel M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genetics. 2003;34(2):154–156.

Ference BA, et al. LDL-C lowering and cardiovascular risk: PCSK9 genetic studies. JAMA. 2017;318(3):233–244.

Kwon HJ, et al. Association between circulating PCSK9 and severity of coronary and carotid atherosclerosis. Atherosclerosis. 2020; 308:8–14.

Tang ZH, et al. PCSK9 promotes inflammation and apoptosis in macrophages. Atherosclerosis. 2017; 262:113–122.

Sabatine MS, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine. 2017;376(18):1713–1722

Robinson JG, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. NEJM. 2015;372(16):1489–1499.

Roth EM, et al. PCSK9 inhibition in high-risk patients: effect on multifocal atherosclerosis. Cardiovascular Drugs and Therapy. 2020;34(5):587–595.

Basiak M, et al. Epigenetic regulation of PCSK9: A potential marker in atherosclerosis. International Journal of Molecular Sciences. 2022;23(3):1098.